melanoma

News

Third time lucky for Replimune as FDA OKs melanoma drug

At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.

News

Adcomm backs Replimune melanoma drug, despite data concern

Replimune's RP1 immunotherapy for melanoma clears advisory committee vote by 10 to three, despite FDA concerns about the design of the IGNYTE study.

News

Another LAG-3 setback as Regeneron drug fails phase 3 trial

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

News

FDA hands another rejection to Replimune's melanoma therapy

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.

News

Data builds behind Moderna's skin cancer vaccine

Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.

Oncology

Interview at ESMO 2025 with Inge Marie Svane

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

Third time lucky for Replimune as FDA OKs melanoma drug

Adcomm backs Replimune melanoma drug, despite data concern

Another LAG-3 setback as Regeneron drug fails phase 3 trial

FDA hands another rejection to Replimune's melanoma therapy

Data builds behind Moderna's skin cancer vaccine

ESMO25: Immuno-therapies and translational research in oncol...

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

melanoma

Editor's Picks